Validation of cardiovascular risk scores in a liver transplant population

Liver Transplantation

Volumn 12, Issue 3, 2006, Pages 394-401

  Guckelberger, Olaf ^a   Mutzke, Florian ^a   Glanemann, Matthias ^a   Neumann, Ulf P ^a   Jonas, Sven ^a   Neuhaus, Ruth ^a   Neuhaus, Peter ^a   Langrehr, Jan M ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; CREATININE; CYCLOSPORIN A; GLUCOSE; STEROID; TSUKUBAENOLIDE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; AREA UNDER THE CURVE; BODY MASS; CALCULATION; CALIBRATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DISCRIMINANT ANALYSIS; FATALITY; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INDIVIDUALIZATION; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PREVALENCE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; REVIEW; RISK ASSESSMENT; SCORING SYSTEM; SEX DIFFERENCE; SYSTOLIC BLOOD PRESSURE; VALIDATION STUDY;

ADULT; AGE DISTRIBUTION; AGED; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; FEMALE; HEART FUNCTION TESTS; HUMANS; LIVER FAILURE; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; ROC CURVE; SEVERITY OF ILLNESS INDEX; SEX DISTRIBUTION; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS;

EID: 33645295755     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.20722     Document Type: Review

References (30)

1. Lerut J, Matthys J, Lemaire J, Van Thuyne V, Ciccarelli O, Goffette P, et al. Adult liver transplantation at UCL: update 2002. Acta Gastroenterol Belg 2004;67:188-196.
2. Johnston SD, Morris JK, Cramb R, Gunson BK, Neuberger J. Cardiovascular morbidity and mortality after orthotopic liver transplantation. Transplantation 2002;73:901-906.
3. Fernandez-Miranda C, Sanz M, dela Calle A, Loinaz C, Gomez R, Jimenez C, et al. Cardiovascular risk factors in 116 patients 5 years or more after liver transplantation. Transpl Int 2002; 15:556-562.
4. Neal DA, Tom BD, Luan J, Wareham NJ, Gimson AE, Delriviere LD, et al. Is there disparity between risk and incidence of cardiovascular disease after liver transplant? Transplantation 2004;77:93-99.
5. Guckelberger O, Byram, A, Klupp J, Neumann UP, Glanemann M, Stockmann M, et al. Coronary event rates in liver transplant recipients reflect the increased prevalence of cardiovascular risk-factors. Transpl Int 2005; 18:967-974.
6. Abbasoglu O, Levy MF, Brkic BB, Testa G, Jeyarajah DR, Goldstein RM, et al. Ten years of liver transplantation: an evolving understanding of late graft loss. Transplantation 1997;64:1801-1807.
7. Ducloux D, Kazory A, Chalopin JM. Predicting coronary heart disease in renal transplant recipients: a prospective study. Kidney Int 2004;66:441-447.
8. Kasiske BL, Chakkera HA, Roel J. Explained and unexplained ischemic heart disease risk after renal transplantation. J Am Soc Nephrol 2000;11:1735-1743.
9. Brindle P, Emberson J, Lampe F, Walker M, Whincup P, Fahey T, Ebrahim S. Predictive accuracy of the Framingham coronary risk score in British men: prospective cohort study. BMJ 2003;327:1267.
10. Marrugat J, D'Agostino R, Sullivan L, Elosua R, Wilson P, Ordovas J, et al. An adaptation of the Framingham coronary heart disease risk function to European Mediterranean areas. J Epidemiol Commun Health 2003;57:634-638.
11. de Visser CL, Bilo HJ, Thomsen TF, Groenier KH, Meyboom-de Jong B. Prediction of coronary heart disease: a comparison between the Copenhagen risk score and the Framingham risk score applied to a Dutch population. J Intern Med 2003;253:553-562.
12. Bastuji-Garin S, Deverly A, Moyse D, Castaigne A, Mancia G, de Leeuw PW, et al. The Framingham prediction rule is not valid in a European population of treated hypertensive patients. J Hypertens 2002;20:1973-1980.
13. WHO Department of Noncommunicable Disease Surveillance. Definition, Diagnosis and Classification of Diabetes Mellitus and Its Complications, Report of a WHO Consultation, Part 1, Diagnosis and Classification of Diabetes Mellitus. Geneva: World Health Organization, 1999.
14. 1999 World Health Organization. International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee. J Hypertens 1999;17:151-183.
15. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837-1847.
16. Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study. Circulation 2002:105:310-315.
17. Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003;24:987-1003.
18. Guckelberger O, Bechstein WO, Neuhaus R, Luesebrink R, Lemmens HP, Kratschmer B, et al. Cardiovascular risk factors in long-term follow-up after orthotopic liver transplantation. Clin Transplant 1997;11:60-65.
19. Canzanello VJ, Schwartz L, Taler SJ, Textor SC, Wiesner RH, Porayko MK, Krom RA. Evolution of cardiovascular risk after liver transplantation: a comparison of cyclosporine A and tacrolimus (FK506). Liver Transpl Surg 1997;3:1-9.
20. Jain A, Reyes J, Kashyap R, Rohal S, Abu-Elmagd K, Starzl T, Fung J. What have we learned about primary liver transplantation under tacrolimus immunosuppression? Long-term follow-up of the first 1000 patients. Ann Surg 1999;230:441-448; discussion, 448-449.
21. Charco R, Cantarell C, Vargas V, Capdevila L, Lazaro JL, Hidalgo E, et al. Serum cholesterol changes in long-term survivors of liver transplantation: a comparison between cyclosporine and tacrolimus therapy. Liver Transpl Surg 1999;5:204-208.
22. Canzanello VJ, Textor SC, Taler SJ, Schwartz LL, Porayko MK, Wiesner RH, Krom PA. Late hypertension after liver transplantation: a comparison of cyclosporine and tacrolimus (FK 506). Liver Transpl Surg 1998;4:328-334.
23. Mor E, Facklam D, Hasse J, Sheiner P, Emre S, Schwartz M, Miller C. Weight gain and lipid profile changes in liver transplant recipients: long-term results of the American FK506 Multicenter Study. Transplant Proc 1995;27:1126.
24. Pratschke J, Neuhaus R, Tullius SG, Haller GW, Jonas S, Steinmueller T, et al. Treatment of cyclosporine-related adverse effects by conversion to tacrolimus after liver transplantation. Transplantation 1997;64:938-940.
25. Neal DA, Gimson AE, Gibbs P, Alexander GJ. Beneficial effects of converting liver transplant recipients from cyclosporine to tacrolimus on blood pressure, serum lipids, and weight. Liver Transpl 2001;7:533-539.
26. Rabkin JM, Corless CL, Rosen HR, Olyaei AJ. Immunosuppression impact on long-term cardiovascular complications after liver transplantation. Am J Surg 2002;183:595-599.
27. Haq IU, Ramsay LE, Yeo WW, Jackson PR, Wallis EJ. Is the Framingham risk function valid for northern European populations? A comparison of methods for estimating absolute coronary risk in high risk men. Heart 1999;81:40-46.
28. Empana JP, Ducimetiere P, Arveiler D, Ferrieres J, Evans A, Ruidavets JB, et al. Are the Framingham and PROCAM coronary heart disease risk functions applicable to different European populations? The PRIME Study. Eur Heart J 2003;24:1903-1911.
29. Chambless LE, Dobson AJ, Patterson CC, Raines B. On the use of a logistic risk score in predicting risk of coronary heart disease. Stat Med 1990;9:385-396.
30. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts). Atherosclerosis 2004;173:381-391.